Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05386888` - A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC	Phase 2
Recruiting	`NCT05128630` - Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.	Phase 2
Active, not recruiting	`NCT05027165` - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Recruiting	`NCT05311709` - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	Phase 2
Recruiting	`NCT04351256` - Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy	Phase 2
Active, not recruiting	`NCT04392505` - Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study	Phase 2
Recruiting	`NCT05718297` - Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT06467383` - A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Recruiting	`NCT04952168` - Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC	Phase 2
Recruiting	`NCT04830826` - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting	`NCT05757843` - Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	Phase 2
Active, not recruiting	`NCT03999710` - Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT03454685` - The Role of Microbiota on the Development of Lung Cancer
Not yet recruiting	`NCT05177497` - SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC	Phase 2
Recruiting	`NCT04202809` - Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.	Phase 2
Recruiting	`NCT04585490` - Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	Phase 3
Recruiting	`NCT04654364` - Lung Cancer Registry
Recruiting	`NCT05344209` - Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer	Phase 2
Withdrawn	`NCT03130829` - To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC	N/A
Recruiting	`NCT04680377` - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

NCT number	NCT05611879
Study type	Interventional
Source	Beijing Tsinghua Chang Gung Hospital
Contact	Fan Yang, Dr.
Phone	+86-10-56112345
Email	Yfa01087@btch.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	March 12, 2023
Completion date	April 30, 2024

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms